Equillium, INC

Equillium, Inc. announced its first quarter 2026 financial results, highlighting progress in its EQ504 program and a strengthened cash position.

Equillium, Inc. announced its fourth quarter and full year 2025 financial results, highlighting a strategic focus on EQ504 and securing financing to extend its operational runway into 2029.

Equillium, Inc. announced a private placement of common stock and pre-funded warrants to RA Capital Healthcare Fund, L.P., raising approximately $35.0 million to advance its EQ504 program and for general corporate purposes.

Equillium, Inc. announced third quarter 2025 financial results, a $30 million financing close, and plans to initiate a Phase 1 clinical study for its novel ulcerative colitis therapeutic, EQ504, in mid-2026.

Equillium, Inc. announced the formal engagement of Crowe LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Equillium, Inc. announced significant corporate governance changes, including auditor dismissal, director resignations, and the termination of a key collaboration agreement with Biocon, amidst a going concern warning.

Equillium, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $5.3 million and a cash balance of $61.3 million, while advancing its EQ504 program.

Equillium, a clinical-stage biotech, reported increased net losses and a strategic pivot to its EQ504 program, bolstered by a $30 million private placement and termination of its itolizumab collaborations.

Equillium, Inc. announced a $30 million private placement and a strategic pivot to its EQ504 program, following the termination of its lead itolizumab clinical development due to unfavorable FDA feedback and trial results.

Equillium reports Q1 2025 results with a net loss of $8.7 million and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Equillium, Inc. reports Q3 2024 results, pausing development of EQ101 and EQ302 to prioritize itolizumab (EQ001) after Ono Pharmaceutical Co., Ltd. option expires.

Equillium Inc. reports a net income of $468,000 for the three months ended June 30, 2024, driven by revenue from its Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd.

Equillium, a biotechnology company, reported significant losses for 2025 but secured $35 million in March 2026 to fund the advancement of its lead candidate, EQ504, into Phase 1 clinical trials by mid-2026.

Equillium's Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) failed to meet primary endpoints, raising concerns about the company's future and ability to continue as a going concern.

Equillium, Inc. released its 10-K filing, outlining its clinical development programs for EQ101, EQ302, and itolizumab (EQ001), along with its financial status.

Equillium, Inc. Senior Vice President and COO Christine Zedelmayer exercised options and sold 14,584 shares of common stock.

Equillium, Inc. President and CSO Stephen Connelly reported the sale of 230,975 shares of common stock across two days in June 2026.

Principal Accounting Officer Tom Penny exercised options and sold 65,000 shares of Equillium, Inc. common stock.

Director Martha J. Demski was granted 70,000 stock options in Equillium, Inc. as part of a standard equity compensation package.

Equillium, Inc. director Mark Pruzanski was granted 70,000 stock options as part of his compensation package.

Equillium, Inc. Chairman Daniel Bradbury was granted 70,000 stock options as part of his director compensation package.

Equillium, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026, to vote on key proposals including a reverse stock split, an increase in authorized shares, director elections, and auditor ratification.

Equillium, Inc. is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Equillium, Inc. will hold its annual stockholders meeting on May 21, 2025, featuring proposals including the election of directors, a potential reverse stock split, ratification of KPMG as the auditor, and an amendment to the equity incentive plan.

Equillium, Inc. is asking stockholders to vote on key proposals at its upcoming annual meeting, including a reverse stock split, election of directors, and an amendment to the company's equity incentive plan.

Equillium, Inc. will hold its annual stockholders meeting on May 22, 2024, to vote on director elections, a potential reverse stock split, auditor ratification, executive compensation, and the frequency of executive compensation votes.

Equillium, Inc. is holding its 2024 annual meeting of stockholders on May 22, 2024, to vote on key proposals including a reverse stock split and the election of directors.

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Equillium, Inc.

Decheng Capital and Xiangmin Cui have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 8.9% in Equillium, Inc.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 5.3% in Equillium, Inc. common stock as of April 1, 2026.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Equillium, Inc., primarily through shared voting and dispositive power.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Equillium, Inc., holding over 6 million common shares.

Janus Henderson Group plc has reported a significant 9.99% beneficial ownership stake in EQUILLIUM, INC., holding over 6 million shares.